Alumis Presents 28-Week Data From Open Label Extension Period Of Phase 2 STRIDE Trial Of ESK-001; Says '28-week Data Show ESK-001 Was Generally Well Tolerated and Most Patients Treated With the Top Dose of 40 Mg Twice Daily Achieved PASI 75'
Alumis Presents 28-Week Data From Open Label Extension Period Of Phase 2 STRIDE Trial Of ESK-001; Says '28-week Data Show ESK-001 Was Generally Well Tolerated and Most Patients Treated With the Top Dose of 40 Mg Twice Daily Achieved PASI 75'
Alumis展示ESk-001第2階段STRIDE試驗開放延長期28週數據；表示'28週數據顯示ESk-001一般耐受性良好，大多數接受每天40毫克的最高劑量治療的患者實現了PASI 75'
Alumis Presents 28-Week Data From Open Label Extension Period Of Phase 2 STRIDE Trial Of ESK-001; Says '28-week Data Show ESK-001 Was Generally Well Tolerated and Most Patients Treated With the Top Dose of 40 Mg Twice Daily Achieved PASI 75'
Alumis展示ESk-001第2階段STRIDE試驗開放延長期28週數據；表示'28週數據顯示ESk-001一般耐受性良好，大多數接受每天40毫克的最高劑量治療的患者實現了PASI 75'
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間